762 results match your criteria Expert Review of Endocrinology & Metabolism [Journal]


Update on central precocious puberty: from etiologies to outcomes.

Expert Rev Endocrinol Metab 2019 Feb 12:1-8. Epub 2019 Feb 12.

b Department of Pediatrics/Division of Pediatric Endocrinology and Diabetology , Riley Hospital for Children, Indiana University School of Medicine , Indianapolis , IN , USA.

Introduction: Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2019.1575726DOI Listing
February 2019

Treatment for polycystic ovary syndrome: a critical appraisal of treatment options.

Authors:
Shahla Nader

Expert Rev Endocrinol Metab 2008 May;3(3):349-359

a Professor, Departments of Obstetrics and Gynecology and Internal Medicine (Endocrinology), University of Texas Medical School - Houston, 6431 Fannin Street, Suite 3604, Houston, TX 77030, USA.

The management of polycystic ovary syndrome (PCOS) usually spans a woman's reproductive years. While the treatment of symptoms is a primary concern, given its long-term nature, the benefits and potential risks need to be assessed and balanced. The variability of presentation coupled with the phenotypic diversity of this patient population, requires the individualization of treatment to each patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.3.3.349DOI Listing

Bone mineral density and vitamin D in PCOS and hirsutism.

Expert Rev Endocrinol Metab 2013 Sep;8(5):449-459

a Department of Endocrinology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in reproductive-aged women. The majority of hirsute patients are diagnosed with PCOS. Hyperandrogenemia, central obesity and insulin resistance may protect patients with PCOS from osteoporosis, whereas increased cortisol levels, low growth hormone and amenorrhea may be associated with decreased bone mineral density (BMD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2013.827384DOI Listing
September 2013

Octreotide for acromegaly.

Expert Rev Endocrinol Metab 2007 Mar;2(2):129-145

b Ospedali Riuniti, Division of Endocrinology, Bergamo, Italy.

Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance. Safe growth hormone and normal insulin-like growth factor I values are reached in 50-60% of unselected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.2.129DOI Listing

Improving wound-healing outcomes in diabetic foot ulcers.

Expert Rev Endocrinol Metab 2007 Mar;2(2):205-213

d Discipline of Medicine, University of Sydney, Blackburn Building, D06; Department of Endocrinology and Diabetes Centre, Royal Prince Alfred Hospital; NSW, Sydney, Australia.

The prevalence of diabetes is increasing worldwide and has been forecasted to double in the next 20 years. The major increase in morbidity and mortality of diabetes is due to the development of both macro- and microvascular complications, including failure of the wound-healing process. Foot ulcers occur in 15% of all patients with diabetes and precede 84% of all lower-leg amputations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.2.205DOI Listing

Endocrinopathy of HFE-related hemochromatosis.

Expert Rev Endocrinol Metab 2007 Mar;2(2):277-286

b South Infirmary Victoria University Hospital, Consultant Endocrinologist, Department of Endocrinology, Old Blackrock Road, Cork, Ireland.

Hereditary hemochromatosis is a condition affecting many organs, as reflected by the fact that it is managed variably by hematologists, gastroenterologists, rheumatologists and endocrinologists, depending on local preferences. A potential pitfall of this approach is that certain aspects of diagnosis and management may be overlooked, particularly if they fall beyond the normal scope of practice of the specialist physician concerned. The purpose of this article is to review the nature of the endocrine complications of hereditary hemochromatosis, which have changed dramatically since the condition was first described over 100 years ago. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.2.277DOI Listing

Pediatric diabetic ketoacidosis management in the era of standardization.

Expert Rev Endocrinol Metab 2012 Jul;7(4):433-443

a Seattle Children's Hospital, Division of Endocrinology and Diabetes, 4800 Sand Point Way NE, Seattle, WA 98105, USA.

Up to 70% of children with new-onset Type 1 diabetes mellitus (T1DM) present with diabetic ketoacidosis (DKA), with most cases initially assessed by their primary care provider. DKA is the most common cause of death in children with T1DM, mainly related to cerebral edema that occurs at a frequency of 0.15-4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.12.37DOI Listing

Ovarian surgery and follicular reserve.

Expert Rev Endocrinol Metab 2006 Nov;1(6):743-752

a Professor, University Hospitals Schleswig-Holstein, Campus Kiel, Department of Obstetrics and Gynecology, Michaelisstr. 16, 24105 Kiel, Germany.

In patients with cystic ovarian pathology, such as endometriomas, polycystic ovary syndrome, teratomas or benign tumors, there is a tendency towards abnormal ovarian function. Anovulation and sterility may occur. This review will summarize the normal physiology of the female gonad and the development of oogenesis from initial reproductive age to the menopause. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.1.6.743DOI Listing
November 2006
1 Read

Monitoring bone mass, bone density and bone geometry in children and adolescents.

Authors:
Stefano Mora

Expert Rev Endocrinol Metab 2006 Mar;1(2):297-307

a Senior Researcher, San Raffaele Scientific Institute, Laboratory of Pediatric Endocrinology, Via Olgettina 60, 20132, Milan, Italy.

The number of articles dealing with pediatric bone mass measurements has flourished during the last decade. The reasons include the awareness that bone gained early in life is an important factor in determining the risk of osteoporosis later in life and the expanding number of pediatric diseases associated with low bone mass. Dual-energy x-ray absorptiometry is the most common method for measurement of bone mineral content or bone mineral density. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.1.2.297DOI Listing

Metabolic consequences of prematurity.

Expert Rev Endocrinol Metab 2006 Mar;1(2):209-218

c Department of Pediatric Endocrinology, Diabetes and Metabolism, Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA, 15213-2583, USA.

A considerable body of scientific evidence now links major diseases of middle-older age, such as the metabolic syndrome, diabetes mellitus and atherosclerotic heart disease, to in utero and perinatal events. Based on replicated epidemiological observations in humans, and experimental evidence in animal models, the data suggest that a period of plasticity during development imposes permanent influences on the way that the organism adapts to the surrounding environment many years later, perhaps via epigenetic and other post-translational modifications of genetic programming, such as regulation of the cell cycle and hormonal programming of metabolic pathways. A critical period appears to be the third trimester, hitherto considered as deprivation of nutrition or other essential factors in utero. Read More

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/17446651.1.2.209
Publisher Site
http://dx.doi.org/10.1586/17446651.1.2.209DOI Listing
March 2006
1 Read

Nutritional rickets: nature or nurture?

Authors:
Abdullah Bereket

Expert Rev Endocrinol Metab 2006 Sep;1(5):661-671

a Professor of Pediatrics and Pediatric Endocrinology, Marmara University, School of Medicine, Division of Pediatric Endocrinology, Bozkir sokak No: 4/7 Selamiçesme, Istanbul, Turkey.

Rickets is a mineralization disorder of the growing bone. Nutritional rickets is still prevalent in many parts of the world. Although vitamin D deficiency plays a central role in the pathogenesis of this disease, calcium deficiency and genetic factors may also cause or contribute to the development of rickets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.1.5.661DOI Listing
September 2006

Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes.

Expert Rev Endocrinol Metab 2007 May;2(3):399-406

b Head, Section on Medical Neuroendocrinology, National Institutes of Health, Reproductive Biology and Medicine Branch, National Institutes of Child Health and Human Development, 10 Center Drive, Bldg 10, CRC, RM 1-E 3140, MSC 1109, Bethesda MD 20892-1109, USA.

Pheochromocytomas and other sympathetic paragangliomas are rare tumors of the adrenal gland or extra-adrenal chromaffin tissue. Mutations of the genes encoding three subunits of the mitochondrial enzyme succinate dehydrogenase give rise to hereditary paraganglioma. We will review the distinct clinical phenotypes of familial paraganglioma syndromes associated with mutations in genes encoding for three different subunits of succinate dehydrogenase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.3.399DOI Listing

Molecular pathogenesis of renal pseudohypoaldosteronism type 1.

Authors:
Felix G Riepe

Expert Rev Endocrinol Metab 2007 May;2(3):407-419

a University Hospital Schleswig-Holstein, Division of Pediatric Endocrinology, Department of Pediatrics, Campus Kiel, 24105 Kiel, Germany.

Pseudohypoaldosteronism is a rare heterogeneous syndrome of mineralocorticoid resistance resulting in insufficient potassium and hydrogen secretion. Pseudohypoaldosteronism type 1 is characterized by mineralocorticoid resistance leading to neonatal salt loss, dehydration and failure to thrive. At least two different forms of pseudohypoaldosteronism type 1 can be distinguished, showing either a systemic or renal form of mineralocorticoid resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.3.407DOI Listing

Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus.

Expert Rev Endocrinol Metab 2007 May;2(3):303-312

b Institute for Clinical Research and Development, Parcusstrasse 8, D-5116, Mainz; University of Applied Sciences, Rheinbach, Germany.

Type 2 diabetes is characterized by impaired insulin sensitivity and disturbances in β-cell function. While glimepiride stimulates β-cell secretion and leads to a reduction of blood glucose levels, pioglitazone activates peroxisome proliferator-activated receptor-γ and improves insulin resistance. Combining these two modes of action has been shown to improve glucose and lipid metabolism, and to improve the overall cardiovascular risk in patients with Type 2 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.3.303DOI Listing

Pituitary-directed medical treatment of Cushing's disease.

Expert Rev Endocrinol Metab 2009 May;4(3):263-272

b Clinica di Endocrinologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, 60100 Ancona, Italy.

The treatment of Cushing's disease is very complex and represents a challenge for clinicians. Transphenoidal surgical excision of adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma remains the treatment of choice but, unfortunately, the rate of cure at long-term follow-up is suboptimal and recurrences are high, even in the hands of skilled neurosurgeons. Other treatment options, such as bilateral adrenalectomy and pituitary radiotherapy, are currently in use but no treatment has proven fully satisfactory during the lengthy progress of this chronic and devastating disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.09.10DOI Listing

β-cell regeneration to treat Type 1 diabetes mellitus.

Expert Rev Endocrinol Metab 2008 Jan;3(1):51-60

b Bone Marrow Transplantation Unit, Department of Clinical Medicine, School of Medicine of Ribeirão Preto. University of São Paulo, CEP 14048-900, Ribeirão Preto, Brazil.

Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of the insulin-producing pancreatic β-cells. The autoimmune response begins years before the presentation of hyperglycemic symptoms. At the time of clinical diagnosis, less than 30% of β-cell mass still remains. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.3.1.51DOI Listing
January 2008

Diagnosis, misdiagnosis and management of hyperprolactinemia.

Expert Rev Endocrinol Metab 2006 Jan;1(1):123-132

c St Vincent's University Hospital, Department of Endocrinology, Elm Park, Dublin 4, Ireland.

Hyperprolactinemia is a commonly encountered disorder that suppresses both male and female gonadal function. The etiology includes pituitary tumors, hypothalamic or pituitary stalk lesions, drugs and hypothyroidism. In women, the hyperprolactinemic syndrome is characterized by menstrual disorders with or without galactorrhea, while men present with hypogonadism and related symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.1.1.123DOI Listing
January 2006

Expert Review of Endocrinology & Metabolism: major coverage of the advances in an expanding field.

Authors:
Kjell Öberg

Expert Rev Endocrinol Metab 2006 Jan;1(1):1-2

a Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.1.1.1DOI Listing
January 2006

Pheochromocytoma: pitfalls in the biochemical evaluation.

Expert Rev Endocrinol Metab 2014 Mar 16;9(2):123-135. Epub 2014 Feb 16.

a Department of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, OH, USA.

The current work-up of a patient suspected to have a pheochromocytoma starts with the measurement of plasma or urine metanephrines. Notably, up to a quarter of these patients will have a false positive result. When the plasma or urine metanephrines are less than the 4-fold upper limit of normal, clinicians struggle between the fear of missing a potentially fatal condition and ordering costly follow up tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2014.887985DOI Listing

Postmenopausal osteoporosis: an update on current and future therapeutic options.

Expert Rev Endocrinol Metab 2007 Jan;2(1):79-90

c Professor of Medicine, Wayne State University, Director, Endocrinology Fellowship Program, St. Joseph Mercy Hospital, Reichert health Building, # 3009, 533 Mc Auley Drive, Ypsilanti, MI 48197, USA.

Recent advances in osteoporosis have dramatically changed the management and treatment of this disease. This article reviews the safety and efficacy of US FDA-approved drugs for prevention and treatment of postmenopausal osteoporosis, as well as studies on combination, sequential or intermittent use of these agents. A review of promising agents for osteoporosis therapy is provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2.1.79DOI Listing
January 2007

Sporadic primary hyperparathyroidism: medical and surgical updates.

Expert Rev Endocrinol Metab 2014 Jan 13;9(1):31-44. Epub 2013 Dec 13.

c Loyola University - Endocrinology and Metabolism, 2160 S. First Avenue, Maywood, IL 60153, USA.

This review discusses recent findings on the clinical presentation, evaluation, medical and surgical management of primary hyperparathyroidism. Medical management includes the use of cinacalcet and bisphosphonates for bone loss and correction of vitamin D deficiency. Surgical updates reviewed recent studies on the preoperative localization of the disease, specifically, sestamibi scans, 4DCT and MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2014.867803DOI Listing
January 2014

The value of genetic screening in medullary thyroid cancer.

Expert Rev Endocrinol Metab 2014 Jan 13;9(1):19-29. Epub 2013 Dec 13.

a Department of Medical Therapeutics, Endocrine Unit, Athens University School of Medicine, Alexandra Hospital, Athens, Greece.

Medullary thyroid cancer (MTC) accounts for ~10% of thyroid carcinomas and occurs in sporadic and hereditary forms. Early diagnosis significantly impacts the clinical course, management and outcome of the disease. The identification of germline-activating mutations of the rearranged during transfection oncogene in patients with hereditary MTC led to significant progress in the diagnostic and therapeutic approach, thus improving the quality of care provided, and consequently, disease prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.2014.868772DOI Listing
January 2014

Cell membrane capsule: a novel natural tool for antitumour drug delivery.

Expert Opin Drug Deliv 2019 Feb 11. Epub 2019 Feb 11.

c Department of Hepatobiliary Surgery , Zhejiang Provincial People's Hospital , Hangzhou 310000 , China.

Introduction: Chemotherapy plays an important role in antitumour therapy, but causes serious adverse reactions. So, drug delivery system (DDS) with cell-targeting ability is an important method to reduce adverse reactions while ensuring the effectiveness of chemotherapy. Synthetic drug carriers and DDSs based on cells have proven safety and efficacy, but they also have many deficiencies or limitations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2019.1581762DOI Listing
February 2019

Future perspectives of the pharmacological management of diabetic dyslipidemia.

Expert Rev Clin Pharmacol 2019 Feb 22;12(2):129-143. Epub 2019 Jan 22.

c Division of Endocrinology , Diabetes and Metabolism University of South Carolina School of Medicine Columbia , South Carolina , SC , USA.

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase subtilisin/kexin type 9) or novel anti-diabetic agents (dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon like peptide-1 receptor agonist (GLP-1RA), sodium/glucose cotransporter 2 inhibitors (SGLT2is)) or nutraceuticals (berberine, omega 3 fatty acid, red yeast rice) can be used alone or in combination. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1567328DOI Listing
February 2019
8 Reads

Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

Expert Opin Pharmacother 2019 Jan 7:1-9. Epub 2019 Jan 7.

b Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine , Comprehensive Weight Control Center , New York , NY , USA.

Introduction: Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561867DOI Listing
January 2019

Management of hyponatremia: causes, clinical aspects, differential diagnosis and treatment.

Authors:
Alessandro Peri

Expert Rev Endocrinol Metab 2018 Dec 11:1-9. Epub 2018 Dec 11.

a Sodium Unit, Endocrinology, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio' , University of Florence, Careggi University Hospital , Florence , Italy.

Introduction: Hyponatremia is the most frequent electrolyte disorder in hospitalised patients. Acute and severe hyponatremia may be a life-threatening situation. However, also mild and chronic hyponatremia may negatively affect the health status (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2019.1556095DOI Listing
December 2018
1 Read

Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits.

Stem Cell Investig 2018 14;5:40. Epub 2018 Nov 14.

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Background: There is a general agreement that to ensure promising results of stem cell therapy in patients with diabetes, one must first understand its risks and benefits; thus, if the risk is sufficiently low along with many benefits, it can lead to developing a novel therapeutic approach based on sound science.

Methods: A systematic review and meta-analysis was performed using all available clinical trials to determine the benefits and risks associated with stem cell therapy in patients with diabetes (both T1DM and T2DM). An extensive search was conducted across several databases using all MeSH words regarding stem cell therapy and diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/sci.2018.11.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286886PMC
November 2018
2 Reads

Surgical-pharmacological interactions in the treatment of acromegaly.

Expert Rev Endocrinol Metab 2019 Jan 29;14(1):35-42. Epub 2018 Dec 29.

c Experimental Endocrinology Unit , Hospital de Especialidades, Centro Medico Nacional S. XXI, IMSS , Mexico City , Mexico.

Introduction: Acromegaly requires a multimodal treatment approach that includes surgery by an expert pituitary neurosurgeon, pharmacological treatment with one or more of the available drugs and radiation therapy. These treatment alternatives are not mutually exclusive but rather complement each other when properly indicated in the individual patient. In this review, we summarize and analyze the available data concerning the choice of the surgical approach (microscopy vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17446651.2019.1559729DOI Listing
January 2019
1 Read

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

World J Gastroenterol 2018 Dec;24(46):5189-5202

Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.

Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v24.i46.5189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840PMC
December 2018
8 Reads

Top-down and bottom-up control of stress-coping.

J Neuroendocrinol 2018 Dec 22:e12675. Epub 2018 Dec 22.

Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida.

In this 30th anniversary issue review, we focus on the glucocorticoid modulation of limbic-prefrontocortical circuitry during stress-coping. This action of the stress hormone is mediated by mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) that are co-expressed abundantly in these higher brain regions. Via both receptor types, the glucocorticoids demonstrate, in various contexts, rapid nongenomic and slower genomic actions that coordinate consecutive stages of information processing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jne.12675DOI Listing
December 2018

Management of immune-related adverse events resulting from immune checkpoint blockade in melanoma.

Expert Rev Anticancer Ther 2018 Dec 20. Epub 2018 Dec 20.

a Dermatology Department , Saint-Louis Hospital , Paris , France.

Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but can lead to the appearance of the newly called immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient's treatment course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1562342DOI Listing
December 2018
1 Read

Improving the rates of Aspergillus detection: an update on current diagnostic strategies.

Expert Rev Anti Infect Ther 2019 Jan 17;17(1):39-50. Epub 2018 Dec 17.

d Division of Infectious Diseases, Department of Medicine , University of California-San Diego , San Diego , CA , USA.

Introduction: The spectrum of disease caused by Aspergillus spp. is dependent on the immune system of the host, and ranges from invasive aspergillosis (IA) to chronic pulmonary aspergillosis (CPA). Early and reliable diagnosis of Aspergillus disease is important to decrease associated morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1558054DOI Listing
January 2019
2 Reads

Mipomersen and its use in familial hypercholesterolemia.

Expert Opin Pharmacother 2019 Feb 10;20(2):127-131. Epub 2018 Dec 10.

a Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine , Washington University School of Medicine , St. Louis , MO , USA.

Introduction: Familial Hypercholesterolemia (FH) is an inherited disorder characterized by a defect in the binding and internalization of low-density lipoprotein (LDL) particles, resulting in markedly elevated LDL levels and premature atherosclerosis. It is one of the most common inherited disorders of lipid metabolism. Many FH patients, especially those with homozygous FH do not reach LDL goals with traditional LDL therapies and may require additional, less often used, therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1550071DOI Listing
February 2019
1 Read

Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults.

J Endocr Soc 2018 Dec 14;2(12):1320-1337. Epub 2018 Nov 14.

Endocrine Society, Washington, District of Columbia.

The use of personal continuous glucose monitoring (CGM) has expanded dramatically among individuals with diabetes. CGM systems provide retrospective data, as well as the current glucose value and trend arrow data, which indicate the direction and velocity of changing glucose. In 2017, Aleppo and colleagues developed a simplified approach for adults with diabetes to safely adjust rapid-acting insulin doses using trend arrow information in the Dexcom G5 CGM system. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jes/article/2/12/1320/5181247
Publisher Site
http://dx.doi.org/10.1210/js.2018-00294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243139PMC
December 2018
25 Reads

Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies.

BMJ 2018 Nov 21;363:k4644. Epub 2018 Nov 21.

Toronto 3D (Diet, Digestive Tract, and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, 61 Queen Street East, Toronto, ON, M5C 2T2, Canada

Objective: To assess the effect of different food sources of fructose-containing sugars on glycaemic control at different levels of energy control.

Design: Systematic review and meta-analysis of controlled intervention studies.

Data Sources: Medine, Embase, and the Cochrane Library up to 25 April 2018. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247175PMC
http://dx.doi.org/10.1136/bmj.k4644DOI Listing
November 2018
8 Reads

A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes.

Minerva Endocrinol 2018 Dec;43(4):501-510

Department of Endocrinology and Metabolic Diseases, Aldo Moro University, Bari, Italy.

Introduction: Hypoglycemia is the major limiting factor in the glycemic management of diabetes. Aim of this study was to produce a risk stratification tool to support the medical decision making, by facilitating the identification of patients at higher risk of hypoglycemia.

Evidence Acquisition: A multistep approach was adopted, including a systematic review of observational studies investigating risk factors for severe hypoglycemia in type 2 diabetes (T2DM), followed by an expert input forum to identify factors perceived as relevant and at the same time reliably detectable, to be used for the development of a risk score. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0391-1977.18.02850-XDOI Listing
December 2018
10 Reads

Links between HPA axis and adipokines: clinical implications in paradigms of stress-related disorders.

Expert Rev Endocrinol Metab 2018 Nov 13;13(6):317-332. Epub 2018 Nov 13.

a Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion Hospital, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: In the human organism, a constant interplay exists between the stress system [which includes the activity of the hypothalamic-pituitary-adrenal (HPA) axis] and the adipose tissue. This interplay is mediated by hormones of the HPA axis such as corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and glucocorticoids (GCs) and adipokines secreted by the adipose tissue. Areas covered: In this critical review, the bi-directional interactions between HPA axis and the most studied adipokines such as leptin and adiponectin, as well as the pro-inflammatory adipocytokines tumor necrosis factor (TNF) and interleukin (IL) 6 are presented. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17446651.2018.1
Publisher Site
http://dx.doi.org/10.1080/17446651.2018.1543585DOI Listing
November 2018
10 Reads

Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Expert Opin Pharmacother 2018 Nov 9:1-11. Epub 2018 Nov 9.

c Division of Endocrinology, Diabetes and Nutrition , University of Maryland School of Medicine , Baltimore , MD , USA.

Introduction: Clinicians have many safe and effective options for the treatment of type 2 diabetes that can improve glycemic control and effect other cardio-metabolic parameters. Sodium-glucose transporter-2 inhibitors (SGLT-2) are the most recent class of therapies, have a novel mechanism of action, and provide good glycemic efficacy and a favorable cardiovascular risk profile. Cost-effectiveness data can play an important role in assessing the benefits of this class of therapy in anti-diabetes treatment regimens. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1543408DOI Listing
November 2018
5 Reads

Growth failure in Crohn's disease children: may the first treatment have a role?

Expert Rev Clin Immunol 2018 Nov 7:1-8. Epub 2018 Nov 7.

a Artificial Nutrition Unit , "Bambino Gesù" Children Hospital , Rome , Italy.

Introduction: Growth failure in children is a frequent feature of childhood-onset Crohn's disease (CD), and stunting can persist into adulthood. Growth is an important outcome by which to judge the effectiveness of therapies in children; currently available studies in CD children have focused on the short-term impact of treatments on growth, and there are limited data regarding the long-term effects of treatments upon growth. Areas covered: We designed the present article to review whether the first treatment performed in newly diagnosed CD children may have a role on the future growth course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1543590DOI Listing
November 2018
7 Reads

Revisiting the role of the pathological grading in pediatric adrenal cortical tumors: results from a national cohort study with pathological review.

Mod Pathol 2018 Nov 6. Epub 2018 Nov 6.

Department of Pathology, Groupement Hospitalier Est, Hospices Civils de Lyon, UCBL Lyon 1 University, Lyon, France.

The prognosis of malignant pediatric adrenocortical tumors is closely related to disease stage, which is used to guide perioperative treatment recommendations. However, current scoring systems are inadequate to distinguish between benign and malignant adrenocortical tumors. Robust microscopic prognostic features that could help determine perioperative therapy are also lacking. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-018-0174-8
Publisher Site
http://dx.doi.org/10.1038/s41379-018-0174-8DOI Listing
November 2018
9 Reads
6.190 Impact Factor

Modern management of recurrent miscarriage.

Aust N Z J Obstet Gynaecol 2018 Nov 4. Epub 2018 Nov 4.

Christopher Chen Oocyte Biology Research Laboratory, UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.

Recurrent miscarriage (RM), also known as recurrent pregnancy loss, is a distressing condition affecting around 1% of couples trying to conceive It can be very frustrating for both clinicians and patients as, despite intensive workup, no clear underlying pathology is forthcoming in at least 50% of couples. This leads to despair for patients and leaves clinicians at a loss for how to help. Desperation in both camps can promote the uptake of investigations and interventions of unproven benefit. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajo.12920
Publisher Site
http://dx.doi.org/10.1111/ajo.12920DOI Listing
November 2018
10 Reads

Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care.

Diabetes Ther 2018 Dec 3;9(6):2185-2199. Epub 2018 Nov 3.

Institute for Studies on Diabetes Foundation Inc, Marikina City, Philippines.

Premixed insulins are an important tool for glycemic control in persons with diabetes. Equally important in diabetes care is the selection of the most appropriate insulin regimen for a particular individual at a specific time. Currently, the choice of insulin regimens for initiation or intensification of therapy is a subjective decision. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13300-018-0521-2
Publisher Site
http://dx.doi.org/10.1007/s13300-018-0521-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250631PMC
December 2018
21 Reads

Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Expert Rev Clin Immunol 2019 Jan 13;15(1):73-81. Epub 2018 Nov 13.

a Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine , Hokkaido University , Sapporo , Japan.

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to recent studies, not only APS patients but also incidentally-identified, asymptomatic aPL carriers are able to be stratified in terms of the risk of future thrombotic events, according to the variety and the titer of positive aPL tests and to the non-thrombotic, aPL-associated clinical manifestations. Areas covered: Here, we critically review (1) criteria manifestations of APS, (2) non-criteria manifestations of APS, (3) risk assessment in patients with APS and in aPL carriers, and (4) the potential role of primary thrombosis prophylaxis in aPL carriers. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1543025DOI Listing
January 2019
2 Reads

Investigational drugs in early stage clinical trials for thyrotoxicosis with hyperthyroidism.

Expert Opin Investig Drugs 2018 Nov 31;27(11):831-837. Epub 2018 Oct 31.

a Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Endocrinology Department , Hospital Universitario de Bellvitge , Barcelona , Spain.

Introduction: Thyrotoxicosis with hyperthyroidism is treated with these classical approaches (i) antithyroid drugs to blockade thyroid hormone release and normalize thyroid hormone production and (ii) destruction of the thyroid using radioiodine or surgical removal of the thyroid. The optimal medical therapy, especially for Graves´ disease, remains a subject of debate and there has been little progress in Graves' disease therapeutics over the last decade. Areas covered: Novel treatments of thyrotoxicosis with hyperthyroidism. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2018.1541086DOI Listing
November 2018
27 Reads

JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.

J Clin Lipidol 2018 Sep - Oct;12(5):1086-1094. Epub 2018 Oct 9.

Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:

High-density lipoproteins (HDL) have been known since the 1960s to be associated with protection from atherosclerotic cardiovascular disease. However, the mechanisms of this protection are unclear. The extent to which HDL per se vs other correlated metabolic factors may mitigate atherosclerosis has been seriously questioned. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19332874183038
Publisher Site
http://dx.doi.org/10.1016/j.jacl.2018.09.005DOI Listing
October 2018
9 Reads

Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review.

Adv Ther 2018 Nov 11;35(11):1805-1815. Epub 2018 Oct 11.

Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy.

Polycystic ovary syndrome (PCOS) affects 6-10% of women and could be considered one of the most common endocrine alterations in women of reproductive age. The syndrome is characterized by several hormonal and metabolic alterations, including insulin resistance and hyperandrogenism, which play a severe detrimental role in the patient's fertility. We aimed to offer an overview about drug metabolism in the PCOS population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-018-0810-1
Publisher Site
http://dx.doi.org/10.1007/s12325-018-0810-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224003PMC
November 2018
3 Reads
2.440 Impact Factor

Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up.

Expert Rev Neurother 2018 Oct 4;18(10):793-806. Epub 2018 Oct 4.

a Department of Pediatrics and Pediatric Hematology/Oncology , Klinikum Oldenburg AöR, Medical Campus University Oldenburg , Oldenburg , Germany.

Introduction: Childhood-onset craniopharyngiomas are rare embryonic tumors of low-grade histological malignancy. Severe obesity, physical fatigue, and psychosocial deficits due to hypothalamic tumor involvement have negative impact on quality of life. Initial pretreatment involvement of hypothalamic structures and/or treatment-related lesions result in sequelae clinically associated with impaired social and physical functionality and severe neuroendocrine deficiencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1528874DOI Listing
October 2018
3 Reads

Skin and diabetes: an experts' opinion from the Italian diabetologists and dermatologists of the DiaDex group.

G Ital Dermatol Venereol 2018 Oct;153(5):649-658

Unit of Dermatology, Sant'Antonio Abate Hospital, Trapani, Italy.

The metabolic changes associated with diabetes mellitus (DM) affect a variety of organs and systems, including the skin. Skin lesions are frequently observed in patients with DM, resulting from a complex interaction among biochemical, vascular, immune, and metabolic changes. Cutaneous manifestations may develop at any time in the course of DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.18.06080-7DOI Listing
October 2018
4 Reads
0.491 Impact Factor

Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus.

Expert Opin Biol Ther 2018 11 25;18(11):1113-1121. Epub 2018 Sep 25.

a Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki , AHEPA University Hospital , Thessaloniki , Greece.

Introduction: Early short-term insulin treatment (STIT), defined as insulin administration shortly after diabetes diagnosis for only a brief period of time, is an alternative concept, aiming to entirely revise the perspective of type 2 diabetes (T2DM) management. Areas covered: The present review intends to summarize what is already known regarding early STIT in T2DM and highlight questions and dilemmas from the clinician's point of view, with a discourse on future research agenda. Expert opinion: STIT has the potential to modify the natural history of T2DM, resulting in improved drug-free remission rates by favorably affecting the underlying pathophysiology of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1526278DOI Listing
November 2018
5 Reads